Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Y. Togashi
774 Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion That Lost MHC Class I Expression After Anti-Pd-1 Therapy
Journal of Investigative Dermatology
Biochemistry
Dermatology
Cell Biology
Molecular Biology
Identification of Novel Isoforms of the EML4-ALK Transforming Gene in Non-Small Cell Lung Cancer
Cancer Research
Cancer Research
Oncology
Related publications
Tumor-Infiltrating Lymphocytes in Melanoma
Current Oncology Reports
Oncology
Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma
Clinical Cancer Research
Cancer Research
Oncology
Efficacy of Adoptive Cell Transfer of Tumor-Infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma
Journal of immunotherapy (Hagerstown, Md. : 1997)
Cancer Research
Allergy
Immunology
Pharmacology
CD8+ Enriched "Young" Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma
Clinical Cancer Research
Cancer Research
Oncology
Clinical Scale Zinc Finger Nuclease (ZFN)-driven Gene-Editing of PD-1 in Tumor Infiltrating Lymphocytes (TIL) for the Potential Treatment of Metastatic Melanoma
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Minimally Invasive Liver Resection to Obtain Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy in Patients With Metastatic Melanoma
World Journal of Surgical Oncology
Surgery
Oncology
The Significance of Tumor-Infiltrating Lymphocytes Before and After Neoadjuvant Therapy for Rectal Cancer
Cancer Science
Cancer Research
Medicine
Oncology
Melanoma-Specific MHC-II Expression Represents a Tumour-Autonomous Phenotype and Predicts Response to Anti-Pd-1/Pd-L1 Therapy
Nature Communications
Astronomy
Genetics
Molecular Biology
Biochemistry
Chemistry
Physics
Safety and Tumor Responses With Lambrolizumab (Anti–PD-1) in Melanoma
New England Journal of Medicine
Medicine